Travel restrictions bite Bavarian as rabies vaccine sales plunge

At the end of Q1, Bavarian Nordic presented shrinking sales of vaccines Rabipur/Rabavert against rabies and Encepur against TBE.
Photo: Philip Davali/Ekstra Bladet, Philip Davali
Photo: Philip Davali/Ekstra Bladet, Philip Davali

Danish biotechnology company Bavarian Nordic's vaccine against rabies has been tripped up by the covid-19 pandemic and resulting travel restrictions, the firm's Vice President Investor Relations & Communications Rolf Sass Sørensen tells Ritzau Finans following the publication of the firm's Q1 report.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading